Mostrando 4 resultados de: 4
Publisher
Experimental and Clinical Psychopharmacology(2)
Drug Metabolism and Drug Interactions(1)
Drug Metabolism and Personalized Therapy(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(4)
ODS 17: Alianzas para lograr los objetivos(3)
ODS 5: Igualdad de género(1)
Origen
scopus(4)
Clinical drug-drug interactions: Focus on venlafaxine
ReviewAbstract: Venlafaxine (VEN) is an antidepressant agent widely used nowadays as an alternative to selective serPalabras claves:Drug-drug interactions, pharmacodynamics, pharmacokinetics, VenlafaxineAutores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusVenlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers
ReviewAbstract: Venlafaxine (VEN) is one of the safest and most effective drugs used in the treatment of selective sPalabras claves:Biomarkers, metabolism, pharmacokinetics, Therapeutic drug monitoring (TDM), Venlafaxine (VEN)Autores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusReal-World Clinical Characterization of Subjects With Depression Treated With Antidepressant Drugs Focused on (Non-)Genetic Factors, Pharmacokinetics, and Clinical Outcomes: GnG-PK/PD-AD Study
ArticleAbstract: This work aimed to describe and characterize the GnG-PK/PD-AD study and the population of subjects dPalabras claves:antidepressants, Cytochrome p450, P-Glycoprotein, pharmacogenetics, Real-world settingAutores:Adrián LLerena, Alves G., Falcao A.C., Fortuna A., Magalhães P.Fuentes:scopusPharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (Non-)genetic factors
ArticleAbstract: This work presents the GnG-PK/PD-AD study-a pharmacokinetics/pharmacodynamics (PK/PD) analysis of thPalabras claves:Biomarkers, Fluoxetine, pharmacogenetics, Real-world data, Therapeutic drug monitoringAutores:Adrián LLerena, Alves G., Falcao A.C., Fortuna A., Magalhães P.Fuentes:scopus